Amna Kamil Leads Systematic Review on Factor Xa Inhibitors for Cancer-Associated VTE
Amna Kamil, MS5 at JSMU (Jinnah Sindh Medical University) posted on LinkedIn:
”Publication Alert
Alhamdulillah
Thrilled to announce that my first Systematic Review and Meta-analysis has been published as First Author in Clinical and Applied Thrombosis/Hemostasis (SAGE Journals)
Why this research matters:
Cancer patients face a much higher risk of developing venous thromboembolism (VTE) – a major cause of morbidity and mortality. Traditional anticoagulants (like LMWH or VKAs) have limitations, leading to growing interest in Factor Xa inhibitors (DOACs such as apixaban and rivaroxaban).
What we found:
Factor Xa inhibitors significantly reduced the risk of VTE compared to placebo.
However, they were also linked to a higher risk of major bleeding.
The balance between benefit and risk highlights the importance of individualized patient selection and the need for further large-scale trials.
This work contributes to ongoing discussions on optimizing thromboprophylaxis in high-risk cancer patients, aiming for safer and more effective clinical decision-making.
This marks a special milestone in my research journey. Grateful to my incredible co-authors and mentors for their constant support and teamwork throughout this process.”
Read the full article here.
Title: “Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis”
Authors: Amna Kamil, Sandhiya Prem Kumar, Rumaisa Zulfiqar, Eiman Araib, Bibi Samia Khan, Muhammad Saad Khan, Muhammad Mohsin Khan, Umaimah Naeem, Aminath Waafira

Stay updated with Hemostasis Today.
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion
-
Aug 24, 2026, 16:38PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator